BioAsia 2014: GSK's emerging markets balance and why Seretide generics are no big deal
This article was originally published in Scrip
Executive Summary
Volatility, forex fluctuations and China issues notwithstanding, GlaxoSmithKline maintains that the emerging markets are a good place to be and that the arrival of generic versions of Seretide in these markets is little cause for concern given its tiered pricing approach.